Prescription transdermal patch abuse and accidental pediatric exposure remains a serious problem in the united states - surveillance data to be presented at 2024 american academy of pain medicine annual meeting

Orlando, fl / accesswire / march 4, 2024 / nutriband inc. (nasdaq:ntrb)(nasdaq:ntrbw), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that data on the incidence of transdermal patch abuse and accidental pediatric exposure will be presented at the 2024 american academy of pain medicine (aapm) annual meeting to be held in scottsdale, arizona march 7-10, 2024. the company engaged rocky mountain poison & drug safety (rmpds), a division of denver health and hospital authority, denver, colorado to determine the incidence of abuse and accidental pediatric exposure of transdermal patches containing drugs of abuse in the united states.
NTRB Ratings Summary
NTRB Quant Ranking